Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Idenix Pharmaceuticals (NASDAQ: IDIX) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Idenix and see what CAPS investors are saying about the stock right now.
Idenix facts
|
Headquarters |
Cambridge, Mass. (1998) |
|
Market Cap |
$649.7 million |
|
Industry |
Biotechnology |
|
Trailing-12-Month Revenue |
$34.9 million |
|
Management |
CEO Ronald Renaud |
|
Trailing-12-Month Return on Equity |
(57.5%) |
|
Cash/Debt |
$205.3 million / $0 |
|
Competitors |
Bristol-Myers Squibb |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 14% of the 234 members who have rated Idenix believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those bears, All-Star zzlangerhans, succinctly summed up the Idenix bear case for our community:
I find it difficult to value hepatitis C stocks but Idenix has risen sharply over the last three weeks without a clear precipitant that I can identify. The company announced plans for a phase II trial of all-oral combination of IDX719 and Janssen's simeprevir in their last earnings call, but this was fairly predictable after the announcement of the Janssen collaboration in January. Hepatitis C may still be an exciting and lucrative field but there's loads of competition and Idenix seems to be years behind in the development of all oral regimens.
